Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Intangibles (2021)

Kiniksa Pharmaceuticals International's Change in Intangibles history spans 1 years, with the latest figure at $20.0 million for Q1 2021.

For Q1 2021, Change in Intangibles changed N/A year-over-year to $20.0 million; the TTM value through Dec 2021 reached $20.0 million, changed N/A, while the annual FY2021 figure was $20.0 million, N/A changed from the prior year.
Change in Intangibles reached $20.0 million in Q1 2021 per KNSA's latest filing.
In the past five years, Change in Intangibles ranged from a high of $20.0 million in Q1 2021 to a low of $20.0 million in Q1 2021.